iTeos Therapeutics Quote - ITOS

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

9.22

Bid

9.06

Ask

9.28

Volume

578,897

8.70 Day's Range 9.265

8.41 52 Week Range 18.75

Market Cap

336.731M

Previous Close

8.97

Open

8.97

Last Trade

134

9.22

(priorref)

Last Trade Time

15:00:21

Financial Volume

US$ 5,200,430

VWAP

8.9833

Average Volume (3m)

665,974

Shares Outstanding

36,521,845

Dividend Yield

PE Ratio

-2.99

Earnings Per Share (EPS)

-3.08

Revenue

12.6M

Net Profit

-112.64M

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoin... ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.iteostherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

iTeos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ITOS. The last closing price for iTeos Therapeutics was US$8.97. Over the last year, iTeos Therapeutics shares have traded in a share price range of US$ 8.41 to US$ 18.75.

iTeos Therapeutics currently has 36,521,845 shares outstanding. The market capitalization of iTeos Therapeutics is US$327.60 million. iTeos Therapeutics has a price to earnings ratio (PE ratio) of -2.99.

Form 8-K - Current report

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference...

iTeos to Participate in Upcoming Investor Conferences

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.28	3.13199105145	8.94	9.22	8.41	605798	8.69505429	CS
4	-0.45	-4.65356773526	9.67	10.21	8.41	682035	9.12708885	CS
12	-6.08	-39.7385620915	15.3	18.13	8.41	665974	11.7578203	CS
26	-2.63	-22.194092827	11.85	18.75	8.41	540862	13.70470843	CS
52	-1.27	-12.1067683508	10.49	18.75	8.41	420945	12.70792309	CS
156	-20.08	-68.5324232082	29.3	52.43	8.2	401906	19.19765808	CS
260	-10.48	-53.1979695431	19.7	52.43	8.2	356633	20.99774856	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ARBBARB IOT Group Ltd	US$ 1.29 (128.52%)	12.92M
CREVCarbon Revolution Public Ltd	US$ 5.00 (52.91%)	15.58k
QLYSQualys Inc	US$ 152.50 (18.93%)	118.13k
TMCITreace Medical Concepts Inc	US$ 6.65 (15.45%)	60.45k
PRQRProQR Therapeutics NV	US$ 4.0455 (13.00%)	352
EXASEXACT Sciences Corporation	US$ 50.12 (-29.91%)	1.76M
SMCXDefiance Daily Target 2X Long SMCI ETF	US$ 1.7209 (-28.30%)	4.77M
NVOSNovo Integrated Sciences Inc	US$ 0.1175 (-21.14%)	616.1k
AVNWAviat Networks Inc	US$ 16.75 (-19.97%)	29.82k
EOSEEos Energy Enterprises Inc	US$ 2.69 (-15.41%)	1.75M
SMCISuper Micro Computer Inc	US$ 23.59 (-14.84%)	25.42M
ELABElevai Labs Inc	US$ 0.022 (2.80%)	13.99M
ARBBARB IOT Group Ltd	US$ 1.29 (128.52%)	12.92M
DJTTrump Media and Technology Group Corporation	US$ 35.60 (4.89%)	10.17M
LILMLilium NV	US$ 0.0585 (12.50%)	6.24M